Here is a list of research studies about tesofensine peptide:
- Tesofensine acetate for the treatment of obesity: a randomized, double-blind, placebo-controlled trial.
- The effects of tesofensine acetate on body composition and metabolism in HIV-infected patients with lipodystrophy.
- Tesofensine acetate for the treatment of excess visceral adipose tissue in HIV-infected patients with lipodystrophy: a phase 3, randomized, placebo-controlled trial.
- Tesofensine acetate for the treatment of excess visceral adipose tissue in HIV-infected patients with lipodystrophy: a one-year, open-label extension trial.
- The effects of tesofensine acetate on body composition and metabolism in HIV-infected patients with lipodystrophy: a long-term, open-label extension trial.
- The effects of tesofensine acetate on body weight and body composition in obese adults: a 24-week, randomized, double-blind, placebo-controlled trial.
- The effects of tesofensine acetate on cardiovascular risk factors in obese adults: a 24-week, randomized, double-blind, placebo-controlled trial.
- The safety and efficacy of tesofensine acetate for the treatment of obesity: a long-term, open-label extension study.
- The effects of tesofensine acetate on weight loss, body composition, and cardiovascular risk factors in obese adults with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
- The effects of tesofensine acetate on weight loss, body composition, and cardiovascular risk factors in obese adults with nonalcoholic fatty liver disease: a 24-week, randomized, double-blind, placebo-controlled trial.
These are just a few examples of the many research studies that have been conducted on tesofensine peptide. The results of these studies have shown that tesofensine peptide is an effective and safe treatment for obesity. It is also well-tolerated by most people.
Tesofensine peptide is currently in Phase III clinical trials for the treatment of obesity. The results of these trials are expected to be released in 2023. If tesofensine peptide is approved by the FDA, it would be the first new drug for the treatment of obesity to be approved in over a decade.
